Emerging treatments for essential thrombocythemia

References

• JohanssonPEpidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemiaSemin Thromb Hemost200632317117316673273
   PubMed Web of Science ®Google Scholar
• VardimanJWThieleJArberDAThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood2009114593795119357394
   PubMed Web of Science ®Google Scholar
• JamesCUgoVCasadevallNConstantinescuSNVainchenkerWA JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospectsTrends Mol Med2005111254655416271512
   PubMed Web of Science ®Google Scholar
• VannucchiAMAntonioliEGuglielmelliPPardananiATefferiAClinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisalLeukemia20082271299130718496562
   PubMed Web of Science ®Google Scholar
• BeerPACampbellPJScottLMMPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortBlood2008112114114918451306
   PubMed Web of Science ®Google Scholar
• MurphySIlandHRosenthalDLaszloJEssential thrombocythemia: an interim report from the Polycythemia Vera Study GroupSemin Hematol19862331771823749928
   PubMed Web of Science ®Google Scholar
• TefferiAThieleJVardimanJWThe 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaosCancer2009115173842384719472396
   PubMed Web of Science ®Google Scholar
• HarrisonCNBarefordDButtNGuideline for investigation and management of adults and children presenting with a thrombocytosisBr J Haematol2010149335237520331456
   PubMed Web of Science ®Google Scholar
• WilkinsBSErberWNBarefordDBone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypesBlood20081111607017885079
   PubMed Web of Science ®Google Scholar
• BarbuiTBarosiGBirgegardGPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetJ Clin Oncol201129676177021205761
   PubMed Web of Science ®Google Scholar
• LengfelderEHochhausAKronawitterUShould a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stagesBr J Haematol1998100115239450785
   PubMed Web of Science ®Google Scholar
• CarobbioAAntonioliEGuglielmelliPLeukocytosis and risk stratification assessment in essential thrombocythemiaJ Clin Oncol200826162732273618443353
   PubMed Web of Science ®Google Scholar
• DahabrehIJZoiKGiannouliSZoiCLoukopoulosDVoulgarelisMIs JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemiaLeuk Res2009331677318632151
   PubMed Web of Science ®Google Scholar
• CampbellPJBarefordDErberWNReticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapyJ Clin Oncol200927182991299919364963
   PubMed Web of Science ®Google Scholar
• BarosiGBirgegardGFinazziGResponse criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceBlood2009113204829483319278953
   PubMed Web of Science ®Google Scholar
• CortelazzoSFinazziGRuggeriMHydroxyurea for patients with essential thrombocythemia and a high risk of thrombosisN Engl J Med199533217113211367700286
   PubMed Web of Science ®Google Scholar
• HarrisonCNCampbellPJBuckGHydroxyurea compared with anagrelide in high-risk essential thrombocythemiaN Engl J Med20053531334516000354
   PubMed Web of Science ®Google Scholar
• GisslingerHGoticMHolowieckiJFinal Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia PatientsASH Annual Meeting Abstracts200811211661
   Google Scholar
• BjorkholmMDerolfARHultcrantzMTreatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasmsJ Clin Oncol201129172410241521537037
   PubMed Web of Science ®Google Scholar
• KiladjianJ-JChevretSDosquetCFenauxPChomienneCRainJ-DLong-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi)ASH Annual Meeting Abstracts2008112111746
   Google Scholar
• KiladjianJJMesaRAHoffmanRThe renaissance of interferon therapy for the treatment of myeloid malignanciesBlood2011117184706471521389325
   PubMed Web of Science ®Google Scholar
• BarosiGBirgegardGFinazziGA unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus processBr J Haematol2010148696196319930182
   PubMed Web of Science ®Google Scholar
• SterkersYPreudhommeCLaiJLAcute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletionBlood19989126166229427717
   PubMed Web of Science ®Google Scholar
• MarchioliRFinazziGLandolfiRVascular and neoplastic risk in a large cohort of patients with polycythemia veraJ Clin Oncol200523102224223215710945
   PubMed Web of Science ®Google Scholar
• Alvarez-LarranACervantesFPereiraAObservation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemiaBlood2010116812051210 quiz 387.20508163
   PubMed Web of Science ®Google Scholar
• ScherberRDueckACJohanssonPThe Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patientsBlood2011118240140821536863
   PubMed Web of Science ®Google Scholar
• Hernandez-BoludaJCAlvarez-LarranAGomezMClinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemiaBr J Haematol20111521818821083657
   PubMed Web of Science ®Google Scholar
• CortelazzoSVieroPFinazziGD’EmilioARodeghieroFBarbuiTIncidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemiaJ Clin Oncol1990835565622307991
   PubMed Web of Science ®Google Scholar
• BessesCCervantesFPereiraAMajor vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patientsLeukemia199913215015410025886
   PubMed Web of Science ®Google Scholar
• WangYFiskusWChongDGCotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cellsBlood2009114245024503319828702
   PubMed Web of Science ®Google Scholar
• KiladjianJJCassinatBChevretSPegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraBlood200811283065307218650451
   PubMed Web of Science ®Google Scholar
• KiladjianJJMasseACassinatBClonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cellsLeukemia20102481519152320520643
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHManshouriTPegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraJ Clin Oncol200927325418542419826111
   PubMed Web of Science ®Google Scholar
• RoyLIanottoJCGuilhotJPegylated Interferon Alpha-2a Therapy for Patients with High Risk Essential Thrombocytemia: a Retrospective Analysis on 59 Patients. On Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)ASH Annual Meeting Abstracts2010116211974
   Google Scholar
• TibesRMesaRAMyeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Leuk Lymphoma20115271178118721599574
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJRResults of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF) [abstract]J Clin Oncol201129Suppl Abst 6500.
   Google Scholar
• HarrisonCNKiladjianJAl-AliHKResults of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) [abstract]J Clin Oncol201129Suppl Abst LBA6501.
   Google Scholar
• MoliternoARHexnerERobozGJAn Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled PatientsASH Annual Meeting Abstracts200911422753
   Google Scholar
• VerstovsekSPassamontiFRambaldiADurable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)ASH Annual Meeting Abstracts201011621313
   Google Scholar
• SkovVLarsenTSThomassenMIncreased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasmsLeuk Lymphoma2011
   Web of Science ®Google Scholar
• LeoniFFossatiGLewisECThe histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivoMol Med2005111–1211516557334
   PubMed Web of Science ®Google Scholar
• FurlanAMonzaniVReznikovLLPharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat)Mol Med2011175–635336221365126
   PubMed Web of Science ®Google Scholar
• RambaldiADellacasaCMFinazziGA pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasmsBr J Haematol2010150444645520560970
   PubMed Web of Science ®Google Scholar